Organogenesis Holdings Inc Reports Financial Results for Q2 2024

authorIntellectia.AI1970-01-01
12
ORGO.O
Illustration by Intellectia.AI

Organogenesis Holdings Inc. Reports Financial Results for Q2 2024

Organogenesis Holdings Inc. reported its financial results for the second quarter ending June 30, 2024.

Key Financial Metrics

Metric Q2 2024 Consensus Estimates
Revenue (in millions) $121.85 $121.85
Earnings Per Share (EPS) $0.00 $0.00

Organogenesis reported total revenue of $121.85 million for the second quarter, matching the consensus estimates. The earnings per share (EPS) was recorded at $0, also aligning with the consensus estimates. A year-over-year and quarter-over-quarter comparison could not be conducted due to the lack of provided data from previous periods.

Revenue Performance Across Major Segments

Segment Q2 2024 Revenue Previous Guidance Comparison to Guidance
Advanced Wound Care N/A N/A N/A
Surgical & Sports Medicine N/A N/A N/A

Due to the earnings release not specifying the revenue breakdown across major segments, a detailed analysis of segment performance could not be conducted.

Key Operational Data

No specific operational data was provided in the earnings release.

Comments from Company Officers

The earnings release did not contain any comments from the company's officers.

Dividends or Share Repurchase Program

The earnings release did not announce any dividends or share repurchase programs.

Forward Guidance

The earnings release did not provide any forward guidance.

Stock Price Movement

Following the earnings release, Organogenesis Holdings Inc.’s stock saw a 4.8% increase.

Overall, Organogenesis Holdings Inc. met the expectations with steady performance in revenues and EPS. The stock market reacted positively to the earnings release, as indicated by the increase in stock price.

This report has been organized to present the available data clearly and concisely.

Share